ArticleScience advances2021
A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections.
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Immunological Mechanisms and Machine Learning Applications in Post-COVID-19 Syndrome: A Narrative Review.Microorganisms · 2026Article
- An at-home blood collection device for remote immune monitoring by high-parameter flow cytometry.JCI insight · 2026Article
- Ventilation-Associated Differences in Lower Airway Microbial Signatures and Peripheral Blood Transcriptome Among Critically Ill COVID-19 Patients.Infection and drug resistance · 2026Article
- Review
- Phenotyping of human platelets in response to platelet agonists and inhibitors using multiparameter flow cytometry and unbiased high-dimensional analysis.Research and practice in thrombosis and haemostasis · 2025Article
- Article
- Heterogeneity and longitudinal transcriptomic characteristics of Tregs in COVID-19 patients.Frontiers in immunology · 2025Article
- IL-33 and IL-3 synergistically induce CD25 expression on human basophils without functional IL-2 signaling: a potential marker of severe COVID-19.Frontiers in immunology · 2025Article
- Longitudinal immune profiling uncovers regulatory T cell signatures associated with the progression of COVID-19.Frontiers in immunology · 2025Article
- T Regulatory Cell Subsets Do Not Restore for One Year After Acute COVID-19.International journal of molecular sciences · 2024Article
- Insights from immunomics and metabolomics on the associations between prostatic diseases and coronavirus disease 2019.Prostate international · 2024Article
- Peripheral Blood Mononuclear Cells and Serum Cytokines in Patients with Lupus Nephritis after COVID-19.International journal of molecular sciences · 2024Article
- Regulatory T cells: Supporting lung homeostasis and promoting resolution and repair after lung injury.The international journal of biochemistry & cell biology · 2024Review
- TM9SF1 offers utility as an efficient predictor of clinical severity and mortality among acute respiratory distress syndrome patients.Frontiers in immunology · 2024Article
- Distinct soluble immune checkpoint profiles characterize COVID-19 severity, mortality and SARS-CoV-2 variant infections.Frontiers in immunology · 2024Article
- Immune-Cell-Based Therapy for COVID-19: Current Status.Viruses · 2023Review
- In vitro high-content tissue models to address precision medicine challenges.Molecular aspects of medicine · 2023Review
- Multidimensional analysis of immune cells from COVID-19 patients identified cell subsets associated with the severity at hospital admission.PLoS pathogens · 2023Article
- Dysfunctional phenotype of systemic and pulmonary regulatory T cells associate with lethal COVID-19 cases.Immunology · 2023Article
- Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID.Vaccines · 2023Review
Corrections and comments
- Update of
Authors and funding
14 authors.
Funding
Abstract
Despite recent studies of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), little is known about how the immune response against SARS-CoV-2 differs from other respiratory infections. We compare the immune signature from hospitalized SARS-CoV-2–infected patients to patients hospitalized prepandemic with influenza or respiratory syncytial virus (RSV). Our in-depth profiling indicates that the immune landscape in SARS-CoV-2 patients is largely similar to flu or RSV patients. Unique to patients infected with SARS-CoV-2 who had the most critical clinical disease were changes in the regulatory T cell (T
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.